1. Andrews N.P., Husain M., Dakak N., Quyyumi A.A. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol 2001;37(2):510-6.
2. Blann A. Antiplatelet therapy and the vascular tree. Heart 2006;92(1): 3-4.
3. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326(4):242-50.
4. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326(5):310-8.
5. Kristensen S.D., Lassen J.F., Ravn H.B. Pathophysiology of coronary thrombosis. Semin Interv Cardiol 2000;5(3):109-15.
6. Бокарев И.Н., Аксенова М.Б., Хлевчук Т.В. Острый коронарный синдром и его лечение. М.: УРАО; 2001.
7. Björklund E., Stenestrand U., Lindbäck J. et al. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006;27(10):1146–52.
8. Blazing M.A., De Lemos J.A., Dyke C.K. et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low�molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142(2):211–7.
9. Goodman S.G., Fitchett D., Armstrong P.W. et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coro�nary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107(2):238–44.
10. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999;354(9180):701–7.
11. Бокарев И.Н., Щепотин В.М., Ена Я.М. Внутрисосудистое свертывание крови. К.: Здоровье; 1989.
12. Кукес В.Г., Остроумова О.Д. Кардиомагнил. Новый взгляд на ацетилсалициловую кислоту. Пособие для врачей. М.; 2004.
13. Vane J.R., Flower R.J., Botting R.M. History of aspirin and its mechanism of action. Stroke 1990;21(12 Suppl):IV12-23.
14. Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6):1309-11.
15. Patrono C. Aspirin resistance definition, mechanisms and clinical read-outs. J Thromb Hemost 2003;1(8):1710-3.
16. Остроумова О.Д. Ацетилсалициловая кислота — препарат номер один для лечения сердечно–сосудистых заболеваний. Основные показания к применению, клинические преимущества, эффективные дозы и пути повышения переносимости. РМЖ 2003;11(5):253–5.
17. Patrono C., Coller B., Dalen J.E. et al. Plate-Active Drugs: The relationship among dose, effectiveness and side effects. Chest 2001;119 (1 Suppl):39S–63S.
18. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50(2):127-34.
19. Ambrose J.A., Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med 1996;156(13):1382-94.
20. Davies M.J., Thomas A.C., Knapman P.A., Hangartner J.R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73(3):418-27.
21. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 1971;231(25):232-5.
22. Jarvis B., Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000;60(2):347-77.
23. Yusuf S., Lessem J., Jha P., Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens Suppl 1993;11(4):S61-73.
